IP Library Granted Patent US 12,274,680
Granted Patent B2
US 12,274,680 · App. 18/188,796 · Granted Apr 15, 2025

Treatment of benign prostatic hypertrophy with capsinoids

Inventor: George William Creasy, II (Glen Gardner, NJ)
A61K31/165A61K9/0053A61K31/231A61K31/357A61P13/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,680
App. No.
18/188,796
Granted
Apr 15, 2025
Kind
B2
Abstract

A method for reducing bladder outlet obstruction and/or self-catheterization frequency of a male patient with bladder outlet obstruction (BOO) due to benign prostatic hypertrophy (BPH) is disclosed. The method comprises orally administering to a male patient suffering from BOO due to BPH an effective amount of an active ingredient selected from a capsinoid mixture, enabling the patient suffering from BOO due to BPH to reduce BOO and/or the self-catheterization frequency.

Claims (12)

1. A method for reducing bladder outlet obstruction of a male patient with BPH, consisting essentially of:

administering orally to a male patient suffering from a bladder outlet obstruction (BOO) due to a benign prostatic hypertrophy (BPH) a composition consisting of at least one capsaicinoid and/or at least one capsinoid, in an amount equivalent to 20,000-200,000 Scoville Heat Units (SHU), wherein the amount is effective to reduce the bladder outlet obstruction.

2. The method of claim 1 , wherein the at least one capsaicinoid and/or the at least one capsinoid is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, resiniferatoxin homocapsaicin, homodihydrocapsaicin, capsiate, dihydrocapsiate, nordihydrocapsiate, analogous compositions thereto, and any combination thereof.

3. The method of claim 1 , wherein the at least one capsaicinoid and/or at least one capsinoid is selected from the group consisting of capsaicin, a capsaicin agonist, a capsaicin analogue, and any combination thereof.

4. The method of claim 1 , wherein the at least one capsaicinoid and/or capsinoid includes a synthesized capsaicinoid and/or a synthesized capsinoid.

5. The method of claim 4 , wherein the composition excludes naturally occurring capsaicinoid and/or capsinoid compounds.

6. The method of claim 1 , wherein the amount is equivalent to 40,000 to 80,000 SHU.

7. The method of claim 1 , wherein the amount is equivalent to 2-20 mg of capsaicin.

8. The method of claim 1 , wherein the amount is equivalent to 5-10 mg capsaicin.

9. A method for reducing bladder outlet obstruction of a male patient with BPH, consisting essentially of:

administering orally to a male patient suffering from a bladder outlet obstruction (BOO) due to a benign prostatic hypertrophy (BPH) a composition consisting of at least one capsaicinoid and/or at least one capsinoid, in an amount equivalent to 2-20 mg of capsaicin, wherein the amount is effective to reduce the bladder outlet obstruction.

10. The method of claim 9 , wherein the at least one capsaicinoid and/or the at least one capsinoid is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, resiniferatoxin homocapsaicin, homodihydrocapsaicin, capsiate, dihydrocapsiate, nordihydrocapsiate, analogous compositions thereto, and any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2026
From: CREASY, GEORGE
To: THE POPULATION COUNCIL, INC.
Reel/Frame 073938/0855 →
Continuity (2)
Provisional Application 63375455 · Sep 13, 2022
Related Publication 20240082178A1 · Mar 14, 2024
References Cited (25)
US 5843016A · Lugnani et al. · 1998 [cited by applicant]
US 6048888A · Zisapel · 2000 [cited by applicant]
US 6200573B1 · Locke · 2001 [cited by applicant]
US 6376488B1 · Basha et al. · 2002 [cited by applicant]
US 6410554B1 · Broten et al. · 2002 [cited by applicant]
US 7122173B2 · Yamagata et al. · 2006 [cited by applicant]
US 7446121B2 · Pfefferkorn · 2008 [cited by applicant]
US 7556828B2 · Zhang et al. · 2009 [cited by applicant]
US 9420817B2 · Ebihara et al. · 2016 [cited by applicant]
US 9579364B2 · Kleinberg et al. · 2017 [cited by applicant]
US 9682115B2 · Seipel · 2017 [cited by applicant]
US 10010534B2 · Cox et al. · 2018 [cited by applicant]
US 20040132728A1 · Pullen et al. · 2004 [cited by applicant]
US 20090186896A1 · Ulbrich et al. · 2009 [cited by applicant]
US 20100204319A1 · Archibald · 2010 [cited by examiner]
US 20100210668A1 · Choi et al. · 2010 [cited by applicant]
US 20100331361A1 · Kakizaki et al. · 2010 [cited by applicant]
US 20120172302A1 · Petri et al. · 2012 [cited by applicant]
US 20210046140A1 · Hwang et al. · 2021 [cited by applicant]
US 20210161642A1 · Jen et al. · 2021 [cited by applicant]
US 20220117971A1 · Mudd, Jr. et al. · 2022 [cited by applicant]
CN 114042068A · 2022 [cited by examiner]
HU 0400847A2 · 2005 [cited by examiner]
HU P0400847A2 · 2005 [cited by examiner]
WO WO2009021058A2 · 2009 [cited by examiner]